American Association of Individual Investors

Why Lexicon Pharmaceuticals, Inc.’s (LXRX) Stock Is Down 13.64%

As of Friday, November 07, Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 13.64%, which has investors ...
Yahoo Finance

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

THE WOODLANDS, Texas, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Yesterday, Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) hosted and participated in a roundtable discussion with experts to explore how to ...
Bdcnetwork.com

How Lexicon is tackling the construction industry's massive mental health crisis

The construction industry is ranked among professions as one of the highest for suicides, with a suicide rate four times higher than the national average. As a male-dominated industry, mental health ...
Morningstar

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

THE WOODLANDS, Texas, June 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from a study evaluating the impact of sotagliflozin on hypoglycemia in ...
TipRanks on MSN

Lexicon Pharmaceuticals’ Earnings Call: Optimism Amid Challenges

Lexicon Pharmaceuticals (($LXRX)) has held its Q3 earnings call. Read on for the main highlights of the call. Lexicon Pharmaceuticals’ recent ...
Yahoo Finance

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

THE WOODLANDS, Texas, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company presented additional clinical data and program updates from its Phase 2 ...
Nasdaq

Lexicon Pharmaceuticals to Host Conference Call on Phase 2b Results for Pilavapadin in Diabetic Peripheral Neuropathic Pain

Lexicon Pharmaceuticals, Inc. announced a conference call and webcast scheduled for March 3, 2025, at 8:00 a.m. ET to discuss topline results from the Phase 2b PROGRESS study of pilavapadin (LX9211), ...
Seeking Alpha

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

THE WOODLANDS, Texas, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (LXRX) today announced the completion of patient enrollment in the PROGRESS (A Phase 2b, Dose-ranging, Randomized, ...
Morningstar

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

THE WOODLANDS, Texas, July 18, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that data from a study of patients describing the impact of diabetic peripheral ...
Seeking Alpha

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

Discovered using Lexicon’s unique approach to gene science, pilavapadin (LX9211) is a potent, once-daily, orally delivered, selective, investigational small molecule inhibitor of AAK1, a novel target ...
Nasdaq

Lexicon Pharmaceuticals to Present Sotagliflozin and Pilavapadin Data at the 85th Scientific Sessions of the American Diabetes Association

Lexicon Pharmaceuticals announced that it will present data from a study on sotagliflozin's effects on hypoglycemia in individuals with type 1 diabetes at the upcoming American Diabetes Association's ...